APO RESEARCH · REPORT
Anti-Venom
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
Product & engineering
Understand the product.
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
Selected research
Market Structure
Global Anti-Venom Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
This report provides an overview of the global Anti-Venom market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
Read the full market overview
The study covers key producers of Anti-Venom and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Anti-Venom sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Venom market size, projected growth trends, production technologies, key applications, and end-use industries.
Anti-Venom Segment by Company
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Anti-Venom Segment by Type
Polyvalent Anti-Venom
Monovalent Anti-Venom
Anti-Venom Segment by Application
Non-profit Institutions
Hospitals and Clinic
Anti-Venom Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Venom market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Venom and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Venom.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Anti-Venom market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-Venom manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-Venom in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Anti-Venom in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Polyvalent Anti-Venom
- Monovalent Anti-Venom
Applications
- Non-profit Institutions
- Hospitals and Clinic
Companies covered
- CSL
- Merck
- BTG
- Pfizer
- Haffkine Bio-Pharmaceutical
- Rare Disease Therapeutics
- Flynn Pharma
- Vins Bioproducts
- Bharat Serums and Vaccines
- Serum Biotech
- MicroPharm
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Anti-Venom Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Anti-Venom Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Anti-Venom Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Anti-Venom Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Anti-Venom Market Dynamics
- 2.1 Anti-Venom Industry Trends
- 2.2 Anti-Venom Industry Drivers
- 2.3 Anti-Venom Industry Opportunities and Challenges
- 2.4 Anti-Venom Industry Restraints
3 Anti-Venom Market by Manufacturers
- 3.1 Global Anti-Venom Revenue by Manufacturers (2021-2026)
- 3.2 Global Anti-Venom Sales by Manufacturers (2021-2026)
- 3.3 Global Anti-Venom Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Anti-Venom Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Anti-Venom Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Anti-Venom Manufacturers, Product Type & Application
- 3.7 Global Anti-Venom Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Anti-Venom Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Anti-Venom Players Market Share by Revenue in 2025
- 3.8.3 2025 Anti-Venom Tier 1, Tier 2, and Tier 3
4 Anti-Venom Market by Type
- 4.1 Anti-Venom Type Introduction
- 4.1.1 Polyvalent Anti-Venom
- 4.1.2 Monovalent Anti-Venom
- 4.2 Global Anti-Venom Sales by Type
- 4.2.1 Global Anti-Venom Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Anti-Venom Sales by Type (2021-2032)
- 4.2.3 Global Anti-Venom Sales Market Share by Type (2021-2032)
- 4.3 Global Anti-Venom Revenue by Type
- 4.3.1 Global Anti-Venom Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Anti-Venom Revenue by Type (2021-2032)
- 4.3.3 Global Anti-Venom Revenue Market Share by Type (2021-2032)
5 Anti-Venom Market by Application
- 5.1 Anti-Venom Application Introduction
- 5.1.1 Non-profit Institutions
- 5.1.2 Hospitals and Clinic
- 5.2 Global Anti-Venom Sales by Application
- 5.2.1 Global Anti-Venom Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Anti-Venom Sales by Application (2021-2032)
- 5.2.3 Global Anti-Venom Sales Market Share by Application (2021-2032)
- 5.3 Global Anti-Venom Revenue by Application
- 5.3.1 Global Anti-Venom Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Anti-Venom Revenue by Application (2021-2032)
- 5.3.3 Global Anti-Venom Revenue Market Share by Application (2021-2032)
6 Global Anti-Venom Sales by Region
- 6.1 Global Anti-Venom Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Anti-Venom Sales by Region (2021-2032)
- 6.2.1 Global Anti-Venom Sales by Region (2021-2026)
- 6.2.2 Global Anti-Venom Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Anti-Venom Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Anti-Venom Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Anti-Venom Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Anti-Venom Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Anti-Venom Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Anti-Venom Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Anti-Venom Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Anti-Venom Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Anti-Venom Revenue by Region
- 7.1 Global Anti-Venom Revenue by Region
- 7.1.1 Global Anti-Venom Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Anti-Venom Revenue by Region (2021-2026)
- 7.1.3 Global Anti-Venom Revenue by Region (2027-2032)
- 7.1.4 Global Anti-Venom Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Anti-Venom Revenue (2021-2032)
- 7.2.2 North America Anti-Venom Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Anti-Venom Revenue (2021-2032)
- 7.3.2 Europe Anti-Venom Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Anti-Venom Revenue (2021-2032)
- 7.4.2 Asia-Pacific Anti-Venom Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Anti-Venom Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Anti-Venom Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 CSL
- 8.1.1 CSL Company Information
- 8.1.2 CSL Business Overview
- 8.1.3 CSL Anti-Venom Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 CSL Anti-Venom Product Portfolio
- 8.1.5 CSL Recent Developments
- 8.2 Merck
- 8.2.1 Merck Company Information
- 8.2.2 Merck Business Overview
- 8.2.3 Merck Anti-Venom Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Merck Anti-Venom Product Portfolio
- 8.2.5 Merck Recent Developments
- 8.3 BTG
- 8.3.1 BTG Company Information
- 8.3.2 BTG Business Overview
- 8.3.3 BTG Anti-Venom Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 BTG Anti-Venom Product Portfolio
- 8.3.5 BTG Recent Developments
- 8.4 Pfizer
- 8.4.1 Pfizer Company Information
- 8.4.2 Pfizer Business Overview
- 8.4.3 Pfizer Anti-Venom Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Pfizer Anti-Venom Product Portfolio
- 8.4.5 Pfizer Recent Developments
- 8.5 Haffkine Bio-Pharmaceutical
- 8.5.1 Haffkine Bio-Pharmaceutical Company Information
- 8.5.2 Haffkine Bio-Pharmaceutical Business Overview
- 8.5.3 Haffkine Bio-Pharmaceutical Anti-Venom Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Haffkine Bio-Pharmaceutical Anti-Venom Product Portfolio
- 8.5.5 Haffkine Bio-Pharmaceutical Recent Developments
- 8.6 Rare Disease Therapeutics
- 8.6.1 Rare Disease Therapeutics Company Information
- 8.6.2 Rare Disease Therapeutics Business Overview
- 8.6.3 Rare Disease Therapeutics Anti-Venom Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Rare Disease Therapeutics Anti-Venom Product Portfolio
- 8.6.5 Rare Disease Therapeutics Recent Developments
- 8.7 Flynn Pharma
- 8.7.1 Flynn Pharma Company Information
- 8.7.2 Flynn Pharma Business Overview
- 8.7.3 Flynn Pharma Anti-Venom Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Flynn Pharma Anti-Venom Product Portfolio
- 8.7.5 Flynn Pharma Recent Developments
- 8.8 Vins Bioproducts
- 8.8.1 Vins Bioproducts Company Information
- 8.8.2 Vins Bioproducts Business Overview
- 8.8.3 Vins Bioproducts Anti-Venom Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Vins Bioproducts Anti-Venom Product Portfolio
- 8.8.5 Vins Bioproducts Recent Developments
- 8.9 Bharat Serums and Vaccines
- 8.9.1 Bharat Serums and Vaccines Company Information
- 8.9.2 Bharat Serums and Vaccines Business Overview
- 8.9.3 Bharat Serums and Vaccines Anti-Venom Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Bharat Serums and Vaccines Anti-Venom Product Portfolio
- 8.9.5 Bharat Serums and Vaccines Recent Developments
- 8.10 Serum Biotech
- 8.10.1 Serum Biotech Company Information
- 8.10.2 Serum Biotech Business Overview
- 8.10.3 Serum Biotech Anti-Venom Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Serum Biotech Anti-Venom Product Portfolio
- 8.10.5 Serum Biotech Recent Developments
- 8.11 MicroPharm
- 8.11.1 MicroPharm Company Information
- 8.11.2 MicroPharm Business Overview
- 8.11.3 MicroPharm Anti-Venom Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 MicroPharm Anti-Venom Product Portfolio
- 8.11.5 MicroPharm Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Anti-Venom Value Chain Analysis
- 9.1.1 Anti-Venom Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Anti-Venom Production Mode & Process
- 9.2 Anti-Venom Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Anti-Venom Distributors
- 9.2.3 Anti-Venom Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst